Revolution Medicines (NASDAQ: RVMD) just achieved a massive victory in a Phase 3 pancreatic cancer study. Following this clinical success, the California biotech doubled its fundraising target, aiming for a $2 billion stock and debt offering to draw in new investors.
On Monday, mere hours after revealing the late-stage trial results, Revolution announced an initial $1 billion stock offering. By Wednesday, the company aggressively upgraded that goal. They now plan to sell more than 10.5 million shares of common stock to hit the new $2 billion mark.
Revolution priced this latest raise at $142 per share. While this sits slightly below the recent closing price of $152.54, it marks a massive jump from the company’s previous valuation. Before releasing the trial data, shares hovered around $96. The positive clinical readout immediately sparked a 40% rally.
The late-stage RASolute 302 study drove this financial surge. Revolution’s RAS blocker, daraxonrasib, more than doubled patient survival rates. Patients taking the experimental drug achieved an overall survival of 13.2 months. In contrast, patients on standard chemotherapy survived for just 6.7 months.
CEO Mark Goldsmith described the findings as “potentially transformative” for people facing pancreatic ductal adenocarcinoma. He emphasized that the results highlight daraxonrasib’s power to redefine the treatment landscape. Moving forward, Revolution plans to submit this data to the FDA and push for standard approval.
Industry analysts quickly praised the data. On Tuesday, Stifel informed investors that the strong survival rates easily justify premium pricing. Specifically, Stifel estimates Revolution could charge between $30,547 and $37,318 for a monthly course of daraxonrasib. This pricing structure would generate a total per-patient revenue ranging from $237,556 to $269,051.
Stifel explained that the newly revealed survival benefit directly drives this monthly pricing model, pushing the drug firmly into a premium tier.
Revolution expects to finalize its common stock offering by the end of this week. For more investor relations information on Revolution Medicines please visit www.ir.revmed.com.
The post Revolution Medicines Doubles Stock Offering Target to $2 Billion Following Pancreatic Cancer Breakthrough appeared first on PRISM MarketView.